ALT — Altimmune, Inc.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Market
- Employees: 59
- Website: https://altimmune.com
Latest SEC filings for ALT
- 10-Q — 2026-08-12
- 8-K — 2026-08-12
- 8-K — 2026-07-28
- 8-K — 2026-06-16
- 10-Q — 2026-05-13
- 8-K — 2026-05-13
- SCHEDULE 13G — 2026-05-12
- SCHEDULE 13G — 2026-05-01
- 424B5 — 2026-04-24
- 8-K — 2026-04-24
Latest ALT news
- — Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight (GlobeNewswire Inc.)
- — Altair Semiconductor Integrates Iridium NTN Direct into ALT1350 and ALT1550 Cellular IoT Chipsets (prnewswire.com)
- — Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? (Zacks Investment Research)
- — Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise (marketbeat.com)
Educational tool only — not investment advice.